This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Find out solutions to mitigate the impact from clinicalsupply chain risk and discover how to improve dynamic drug supply forecasting strategies. Join this webinar to learn how supply forecasting and interactive response technology can help biotech companies improve supply planning and distribution while reducing cost and risk.
Awarded by specific function, in which a CRO could provide single or multiple services, such as site monitoring, data management, post-approval monitoring or clinicalsupply services, across numerous protocols. Most often done using the vendor’s systems and standard operating procedures (SOP).
Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. Food and Drug Administration (“FDA”) approval.
Under the agreement, during the option period, Molecular Partners will conduct Phase 1 clinical trials for MP0420, expected to begin in November 2020, and perform all remaining preclinical work for MP0423 and Novartis will conduct Phase 2 and Phase 3 clinical trials, with Molecular Partners as sponsor of these trials.
However, with this kind of promise comes more scientific, ethical and financial questions that healthcare providers and drug development professionals must seriously consider. He is certified in Internal Medicine and Gastroenterology and is also a Fellow of the American College of Gastroenterology.
From pioneering treatments for rare pediatric diseases to exploring natural killer cells for Alzheimers and developing FDA-approved digital therapeutics for fibromyalgia, each episode reveals the scientific ingenuity and personal determination behind medical advances.
In todays clinicalresearch landscape, it is both essential and challenging to accelerate clinical trials. However, achieving this requires drug developers to navigate a highly complex and competitive environment. 1 provider of clinicalresearch solutions , our teams deliver 1.5x Recognized as the 2024 No.
Could you share an example of a specific project or research that you have worked on and the impact it has had in your field? In clinicalresearch, I have brought over 25 compounds to market and supported five more while leading a quality assurance organisation.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content